---
title: "Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Dosing and administration questions"
description: "Dosing and administration questions on Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Dosing, Treatment combinations, and Switching. Questions: How many doses of Shingrix do adults 50 and older need? What is the Shingrix dosing schedule for immunocompromised adults 18 and older? How was the Shingrix 2-to-6-month interval supported in adults 50 and older? Can Shingrix be given at the same visit as other vaccines? 4 further questions follow. 8 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/dosing-and-administration"
published: "2026-11-14T00:11:41-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Shingrix (Zoster Vaccine Recombinant, Adjuvanted) in herpes zoster prevention: Dosing and administration questions

Manufacturer: GlaxoSmithKline Biologicals; GlaxoSmithKline  
Prescribing information: [Shingrix](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF)

Dosing and administration questions that apply to every indication of Shingrix are on [Shingrix (Zoster Vaccine Recombinant, Adjuvanted), all indications: Dosing and administration](https://www.evicenter.com/medical-information/shingrix/dosing-and-administration).

## Dosing

<a id="shingrix-dosing-50-and-older"></a>

### How many doses of Shingrix do adults 50 and older need?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “Administer two doses (0.5 mL each) intramuscularly according to the following schedules:”

Source: [SHINGRIX: Prescribing information, page 3, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=3)

> “• A first dose at Month 0 followed by a second dose administered 2 to 6 months later.”

Source: [SHINGRIX: Prescribing information, page 3, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=3)

<a id="shingrix-dosing-immunocompromised"></a>

### What is the Shingrix dosing schedule for immunocompromised adults 18 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 18 years and older who are or will be at increased risk of herpes zoster due to immunodeficiency or immunosuppression caused by known disease or therapy

> “Administer two doses (0.5 mL each) intramuscularly according to the following schedules:”

Source: [SHINGRIX: Prescribing information, page 3, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=3)

> “• A first dose at Month 0 followed by a second dose administered 2 to 6 months later.”

Source: [SHINGRIX: Prescribing information, page 3, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=3)

> “• For individuals who are or will be immunodeficient or immunosuppressed and who would benefit from a 
> shorter vaccination schedule: A first dose at Month 0 followed by a second dose administered 1 to 2 months 
> later.”

Source: [SHINGRIX: Prescribing information, page 4, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=4)

<a id="shingrix-schedule-0-6-months"></a>

### How was the Shingrix 2-to-6-month interval supported in adults 50 and older?

Applies to: Prevention of herpes zoster (shingles) in adults aged 50 years and older

> “A measure of the immune response that confers protection against HZ is unknown. Anti-gE antibody levels 
> were measured by anti-gE enzyme-linked immunosorbent assay (gE ELISA) and were used to support the 
> dosing schedule.”

Source: [SHINGRIX: Prescribing information, page 20, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=20)

> “In an open-label clinical study, 238 subjects aged 50 years and older received SHINGRIX on either a 0- and 
> 2-month or 0- and 6-month schedule. Non-inferiority of the 0- and 6-month schedule compared with the 0- and 
> 2-month schedule based on anti-gE ELISA GMCs 1 month after the second dose was demonstrated.”

Source: [SHINGRIX: Prescribing information, page 20, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=20)

> “Dosing Schedule: In an open-label clinical study, 238 subjects aged 50 years and older received SHINGRIX as 
> a 0- and 2-month or 0- and 6-month schedule. The safety profile of SHINGRIX was similar when administered 
> according to a 0- and 2-month or 0- and 6-month schedule and was consistent with that observed in Studies 1 
> and 2.”

Source: [SHINGRIX: Prescribing information, page 7, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=7)

## Treatment combinations

<a id="shingrix-coadministration"></a>

### Can Shingrix be given at the same visit as other vaccines?

Applies to: Adults aged 50 years and older given Shingrix concomitantly with another vaccine (open-label studies in the Prescribing Information)

> “According to the CDC, recombinant and adjuvanted vaccines (like SHINGRIX) can be administered concomitantly at different anatomic sites with other adult vaccines.<sup>1</sup> Please visit CDC.gov for complete guidance”

Source: [SHINGRIX: Coadministration, captured 2026-11-14](https://shingrixhcp.com/recommend-administer/coadministration/#:~:text=According%20to%20the%20CDC%2C%20recombinant,visit%20CDC.gov%20for%20complete%20guidance)

> “The Prescribing Information for SHINGRIX contains information regarding the concomitant administration of SHINGRIX with flu, pneumococcal, and Tdap vaccines<sup>2</sup>”

Source: [SHINGRIX: Coadministration, captured 2026-11-14](https://shingrixhcp.com/recommend-administer/coadministration/#:~:text=The%20Prescribing%20Information%20for%20SHINGRIX,with%20flu%2C%20pneumococcal%2C%20and%20Tdap)

> “Data are limited regarding the coadministration of SHINGRIX with other vaccines”

Source: [SHINGRIX: Coadministration, captured 2026-11-14](https://shingrixhcp.com/recommend-administer/coadministration/#:~:text=Data%20are%20limited%20regarding%20the%20coadministration%20of%20SHINGRIX%20with%20other%20vaccines)

Note: The Coadministration page of the Shingrix HCP site attributes the first statement to the CDC and refers readers to CDC.gov for complete guidance.

<a id="shingrix-flu-vaccine"></a>

### Can Shingrix be given with a flu vaccine in adults 50 and older?

Applies to: Adults aged 50 years and older given Shingrix concomitantly with another vaccine (open-label studies in the Prescribing Information)

> “In an open-label clinical study (NCT01954251), subjects aged 50 years and older received 1 dose each of 
> SHINGRIX and quadrivalent influenza vaccine (FLUARIX QUADRIVALENT) at Month 0 and 1 dose of 
> SHINGRIX at Month 2 (n = 413), or 1 dose of FLUARIX QUADRIVALENT at Month 0 and 1 dose of 
> SHINGRIX at Months 2 and 4 (n = 415). The mean age of the population was 63 years; 52% were female. The 
> majority of subjects were White (92%), followed by Asian (6%), and Black (2%); 0.4% were of American 
> Hispanic or Latino ethnicity. There was no evidence for interference in the immune response to any of the 
> antigens contained in SHINGRIX or the coadministered vaccine.”

Source: [SHINGRIX: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=23)

<a id="shingrix-pneumococcal-vaccines"></a>

### Can Shingrix be given with Pneumovax 23 or Prevnar 13 in adults 50 and older?

Applies to: Adults aged 50 years and older given Shingrix concomitantly with another vaccine (open-label studies in the Prescribing Information)

> “In an open-label clinical study (NCT02045836), subjects aged 50 years and older received 1 dose each of 
> SHINGRIX and PNEUMOVAX 23 at Month 0 and 1 dose of SHINGRIX at Month 2 (n = 432), or 1 dose of 
> PNEUMOVAX 23 at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n = 433). The mean age of the 
> population was 63 years; 60% were female. The majority of subjects were White (94%), followed by Black 
> (2%), Asian (2%), and other racial groups (2%); 1% were of American Hispanic or Latino ethnicity.”

Source: [SHINGRIX: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=23)

> “There was no evidence for interference in the 
> immune response to the antigen contained in SHINGRIX or to the 12 evaluated antigens contained in 
> PNEUMOVAX 23 when the two vaccines were administered concomitantly.”

Source: [SHINGRIX: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=23)

> “When Pneumovax 23 was coadministered with the first dose of SHINGRIX, compared to when the first dose of SHINGRIX was given alone, a greater percentage of subjects reported fever, defined as ≥37.5°C/99.5°F (16% vs 7%, respectively) and shivering (21% vs 7%, respectively) within 7 days post-vaccination”

Source: [SHINGRIX: Coadministration, captured 2026-11-14](https://shingrixhcp.com/recommend-administer/coadministration/#:~:text=When%20Pneumovax%2023%20was%20coadministered,respectively%29%20within%207%20days%20post%2Dvaccination)

> “In an open-label clinical study (NCT03439657), subjects aged 50 years and older received 1 dose each of 
> SHINGRIX and PREVNAR 13 at Month 0 and 1 dose of SHINGRIX at Month 2 (n = 449), or 1 dose of 
> PREVNAR 13 at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 (n = 463). The mean age of the 
> population was 63 years; 60% were female. The majority of subjects were White (98%), followed by Black 
> (2%); 0.4% were of American Hispanic or Latino ethnicity.”

Source: [SHINGRIX: Prescribing information, page 24, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=24)

> “There was no evidence for interference in the immune response to the antigens contained in 
> SHINGRIX or PREVNAR 13 when the two vaccines were administered concomitantly.”

Source: [SHINGRIX: Prescribing information, page 24, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=24)

Note: The fever and shivering comparison is from the Coadministration page of the Shingrix HCP site; the other passages are from section 14.8 of the Prescribing Information.

<a id="shingrix-tdap-vaccine"></a>

### Can Shingrix be given with Tdap (Boostrix) in adults 50 and older?

Applies to: Adults aged 50 years and older given Shingrix concomitantly with another vaccine (open-label studies in the Prescribing Information)

> “In an open-label clinical study (NCT02052596), subjects aged 50 years and older received 1 dose each of 
> SHINGRIX and BOOSTRIX at Month 0 and 1 dose of SHINGRIX at Month 2 (n = 412; concomitant 
> administration group), or 1 dose of BOOSTRIX at Month 0 and 1 dose of SHINGRIX at Months 2 and 4 
> (n = 418; sequential administration group). The mean age of the population was 63 years; 54% were female.”

Source: [SHINGRIX: Prescribing information, page 24, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=24)

> “Concomitant administration showed no evidence for interference in the immune response to the antigen 
> contained in SHINGRIX or the antigens contained in BOOSTRIX, with the exception of one of the pertussis 
> antigens (pertactin), which did not meet the non-inferiority criterion: the UL of the 95% CI for the adjusted 
> GMC ratio (sequential administration group/concomitant administration group) for anti-pertactin antibody was 
> 1.58 (non-inferiority criterion <1.5). The clinical significance of the reduced immune response to pertactin is 
> unknown.”

Source: [SHINGRIX: Prescribing information, page 24, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=24)

## Switching

<a id="shingrix-after-zostavax"></a>

### Shingrix after Zostavax: what did the label study in adults 65 and older show?

Applies to: Adults aged 65 years and older previously vaccinated with Zostavax (Zoster Vaccine Live) more than 5 years before enrollment

> “In an open-label clinical study (NCT02581410), subjects aged 65 years and older, who had been previously 
> vaccinated with ZOSTAVAX more than 5 years prior to study enrollment (n = 215) or who had never been 
> vaccinated with ZOSTAVAX (n = 215), received 1 dose of SHINGRIX at Months 0 and 2.”

Source: [SHINGRIX: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=23)

> “The anti-gE antibody (Ab) concentration measured by ELISA 1 month following 2 doses of SHINGRIX in 
> subjects who had previously been vaccinated with ZOSTAVAX was non-inferior to that of subjects who had 
> never been vaccinated with ZOSTAVAX. The upper limit (UL) of the 95% confidence interval (CI) was 1.17 
> (success criterion <1.5) for the anti-gE Ab adjusted geometric mean concentration (GMC) ratio between 
> subjects who had never been vaccinated with ZOSTAVAX and subjects who had been previously vaccinated 
> with ZOSTAVAX. There was no evidence for interference in the immune response to SHINGRIX in subjects 
> previously vaccinated with ZOSTAVAX.”

Source: [SHINGRIX: Prescribing information, page 23, captured 2026-11-14](https://gskpro.com/content/dam/global/hcpportal/en_US/Prescribing_Information/Shingrix/pdf/SHINGRIX.PDF#page=23)

## Related pages
- [Medical information: Shingrix (Zoster Vaccine Recombinant, Adjuvanted): Herpes zoster prevention](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention)
- [Indication](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/indication)
- [Clinical trials](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/safety)
- [Specific populations](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/specific-populations)
- [Access and coverage](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/access-and-coverage)
- [Guidelines](https://www.evicenter.com/medical-information/shingrix--herpes-zoster-prevention/guidelines)
